Apimeds Pharmaceuticals US, Inc. (APUS)
↓ Download CSVKey ratios (FY2025)
-3.9%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Income | -$11.91M | -$1.28M | -$747.4K | — |
| Net Income | -$6.00M | -$1.39M | -$777.7K | — |
| EPS (Diluted) | $-0.55 | $-0.18 | $-0.17 | — |
| Total Assets | $164.18M | $13.1K | $422.1K | — |
| Total Liabilities | $10.84M | $1.37M | $390.2K | — |
| Shareholders' Equity | $153.35M | -$1.36M | $31.9K | -$713.6K |
| Cash & Equivalents | $1.64M | $3.5K | $410.5K | — |
| Operating Cash Flow | -$8.93M | -$733.5K | -$627.8K | — |
| Capital Expenditures | $57.3K | — | — | — |
| Shares Outstanding | 12.58M | 7.90M | 7.90M | — |